Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 288

1.

Prenatal Enzymatic Diagnosis of Lysosomal Storage Diseases using cultured amniotic cells, uncultured chorionic villus samples and fetal blood cells: Hacettepe experience.

Unal C, Ozkara HA, Tanacan A, Fadiloglu E, Lay I, Topçu M, Cakar AN, Beksac MS.

Prenat Diagn. 2019 Aug 14. doi: 10.1002/pd.5547. [Epub ahead of print]

PMID:
31411753
2.

Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Lenalidomide and/or Bortezomib Containing Regimens

Ataca Atilla P, Yalciner M, Atilla E, Idilman R, Beksac M.

Turk J Haematol. 2019 Aug 1. doi: 10.4274/tjh.galenos.2019.2019.0103. [Epub ahead of print]

3.

First trimester complete blood cell indices in early and late onset preeclampsia.

Örgül G, Aydın Haklı D, Özten G, Fadiloğlu E, Tanacan A, Beksaç MS.

Turk J Obstet Gynecol. 2019 Jun;16(2):112-117. doi: 10.4274/tjod.galenos.2019.93708. Epub 2019 Jul 3.

4.

Effect of viral load on pregnancy outcomes in chronic hepatitis B infection.

Unal C, Tanacan A, Ziyadova G, Fadiloglu E, Beksac MS.

J Obstet Gynaecol Res. 2019 Jul 22. doi: 10.1111/jog.14065. [Epub ahead of print]

PMID:
31332897
5.

Changing rates of the modes of delivery over the decades (1976, 1986, 1996, 2006, and 2016) based on the Robson-10 group classification system in a single tertiary health care center.

Cagan M, Tanacan A, Aydin Hakli D, Beksac MS.

J Matern Fetal Neonatal Med. 2019 Jul 24:1-8. doi: 10.1080/14767058.2019.1644619. [Epub ahead of print]

PMID:
31307260
6.

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.

Beksac M, Cengiz Seval G, Kanellias N, Coriu D, Rosiñol L, Ozet G, Goranova-Marinova V, Unal A, Bila J, Ozsan H, Ivanaj A, Balić LI, Kastritis E, Bladé J, Dimopoulos MA.

Haematologica. 2019 Jul 5. pii: haematol.2019.219295. doi: 10.3324/haematol.2019.219295. [Epub ahead of print]

7.
8.

Metabolic Infrastructure of Pregnant Women With Trisomy 21 Fetuses; Metabolomic Analysis.

Nemutlu E, Orgul G, Recber T, Aydin E, Ozkan E, Turgal M, Alikasifoglu M, Kir S, Beksac MS.

Z Geburtshilfe Neonatol. 2019 May 27. doi: 10.1055/a-0877-7869. [Epub ahead of print]

PMID:
31132797
9.

A Cut-off Value for Gestational Week at Birth for Better Perinatal Outcomes in Early- and Late-Onset Fetal Growth Restriction.

Beksac MS, Fadiloglu E, Tanacan A, Mamopoulos A, Basol M, Muresan D, Athanasiadis A.

Z Geburtshilfe Neonatol. 2019 May 17. doi: 10.1055/a-0882-7425. [Epub ahead of print]

PMID:
31100759
10.

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.

Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators.

Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.

PMID:
31097405
11.

PET with Fluorodeoxyglucose F 18/Computed Tomography as a Staging Tool in Multiple Myeloma.

Seval GC, Ozkan E, Beksac M.

PET Clin. 2019 Jul;14(3):369-381. doi: 10.1016/j.cpet.2019.03.009. Epub 2019 Apr 12. Review.

PMID:
31084776
12.

Myasthenia gravis and pregnancy: retrospective evaluation of 27 pregnancies in a tertiary center and comparison with previous studies.

Tanacan A, Fadiloglu E, Ozten G, Gunes AC, Orgul G, Beksac MS.

Ir J Med Sci. 2019 May 9. doi: 10.1007/s11845-019-02029-0. [Epub ahead of print]

PMID:
31073909
13.

A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma.

Cengiz Seval G, Beksac M.

Expert Opin Drug Saf. 2019 Jul;18(7):563-571. doi: 10.1080/14740338.2019.1615051. Epub 2019 May 9. Review.

PMID:
31070945
14.

Human papillomavirus infection and autoimmune disorders: a tertiary center experience.

Donmez HG, Tanacan A, Unal C, Fadiloglu E, Onder SC, Portakal O, Beksac MS.

Pathog Dis. 2019 Apr 1;77(3). pii: ftz028. doi: 10.1093/femspd/ftz028.

PMID:
31034015
15.
16.

Impaired Placentation and Early Pregnancy Loss in Patients with MTHFR Polymorphisms and Type-1 Diabetes Mellitus.

Gurbuz RH, Atilla P, Orgul G, Tanacan A, Dolgun A, Cakar AN, Beksac MS.

Fetal Pediatr Pathol. 2019 Apr 7:1-11. doi: 10.1080/15513815.2019.1600623. [Epub ahead of print]

PMID:
30955395
17.

The importance of proteinuria in preeclampsia and its predictive role in maternal and neonatal outcomes.

Tanacan A, Fadiloglu E, Beksac MS.

Hypertens Pregnancy. 2019 May;38(2):111-118. doi: 10.1080/10641955.2019.1590718. Epub 2019 Apr 2.

PMID:
30939965
18.

Pregnancy outcomes of the patients with anti smooth muscle antibody positivity.

Ünal C, Fadiloglu E, Beksac MS.

Hum Antibodies. 2019 Mar 15. doi: 10.3233/HAB-190365. [Epub ahead of print]

PMID:
30909204
19.

Gestational Outcomes of Pregnancies with Prenatally Detected Gastroschisis and Omphalocele.

Aktoz F, Ozyuncu O, Tanacan A, Fadiloglu E, Unal C, Soyer T, Celik T, Beksac MS.

Fetal Pediatr Pathol. 2019 Aug;38(4):282-289. doi: 10.1080/15513815.2019.1585501. Epub 2019 Mar 20.

PMID:
30892123
20.

Impact of extractable nuclear antigen, anti-double stranded DNA, antiphospholipid antibody, and anticardiolipin antibody positivity on obstetrical complications and pregnancy outcomes.

Tanacan A, Beksac MS, Orgul G, Duru S, Sener B, Karaagaoglu E.

Hum Antibodies. 2019;27(2):135-141. doi: 10.3233/HAB-180359.

PMID:
30856108
21.

Clinical importance of the 75-g glucose tolerance test (GTT) in the prediction of large for gestational age (LGA) fetuses in non-diabetic pregnancies.

Fadiloglu E, Tanacan A, Unal C, Aydin Hakli D, Beksac MS.

J Perinat Med. 2019 Jul 26;47(5):534-538. doi: 10.1515/jpm-2018-0373.

PMID:
30817306
22.

Antenatal hydronephrosis and fetal urine sampling.

Beksac MS, Beksac AT, Tanacan A, Mumusoglu S, Katlan D, Celik HT.

Congenit Anom (Kyoto). 2019 Jan 10. doi: 10.1111/cga.12324. [Epub ahead of print]

PMID:
30629771
23.

Management and the pregnancy outcomes of patients positive for anti-parietal cell antibody.

Fadiloglu E, Unal C, Beksac MS.

Hum Antibodies. 2019;27(2):111-116. doi: 10.3233/HAB-180355.

PMID:
30594922
24.

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.

Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group.

Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10.

PMID:
30545780
25.

Methotrexate Therapy for Ectopic Pregnancies: A Tertiary Center Experience.

Ozyuncu O, Tanacan A, Duru SA, Beksac MS.

Rev Bras Ginecol Obstet. 2018 Nov;40(11):680-685. doi: 10.1055/s-0038-1675807. Epub 2018 Nov 28.

26.

Computerized hybrid decision-making system for hormone replacement therapy in menopausal women.

Bacak HO, Leblebicioglu K, Tanacan A, Beksac MS.

Technol Health Care. 2019;27(1):49-59. doi: 10.3233/THC-181235.

PMID:
30475776
27.

Cultural adaptation and validation of the Turkish CONTILIFE: a quality of life questionnaire for urinary incontinence.

Orhan C, Özgül S, Baran E, Üzelpasacı E, Nakip G, Çinar GN, Beksaç MS, Akbayrak T.

Int Urogynecol J. 2019 Jan;30(1):139-147. doi: 10.1007/s00192-018-3823-z. Epub 2018 Nov 20.

PMID:
30460380
28.

Retrospective analysis of indications for termination of pregnancy.

Ozyuncu O, Orgul G, Tanacan A, Aktoz F, Guleray N, Fadiloglu E, Beksac MS.

J Obstet Gynaecol. 2019 Apr;39(3):355-358. doi: 10.1080/01443615.2018.1506427. Epub 2018 Nov 14.

PMID:
30428730
29.

A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis.

Weisel K, Sonneveld P, Spencer A, Beksac M, Rizzo M, Xu Y, Fahrbach K, Gaudig M, Slavcev M, Dearden L, Lam A.

Leuk Lymphoma. 2019 Jan;60(1):151-162. doi: 10.1080/10428194.2018.1466392. Epub 2018 Nov 8.

PMID:
30407092
30.

Short-term effects of connective tissue manipulation in women with primary dysmenorrhea: A randomized controlled trial.

Özgül S, Üzelpasaci E, Orhan C, Baran E, Beksaç MS, Akbayrak T.

Complement Ther Clin Pract. 2018 Nov;33:1-6. doi: 10.1016/j.ctcp.2018.07.007. Epub 2018 Jul 21.

PMID:
30396605
31.

Factors influencing the success of cord blood collection: a tertiary perinatal medicine center’s experience

Tanaçan A, Yurdakul P, Aktoz F, Örgül G, Beksaç M, Beksaç MS.

Turk J Med Sci. 2018 Oct 31;48(5):961-966. doi: 10.3906/sag-1802-54.

PMID:
30384561
32.

Comparison of different types of twin pregnancies in terms of obstetric and perinatal outcomes: association of vanished twins with methylenetetrahydrofolate reductase (MTHFR) polymorphism(s).

Ozek MA, Karaagaoglu E, Orgul G, Gumruk F, Yurdakök M, Beksac MS.

J Assist Reprod Genet. 2018 Dec;35(12):2149-2154. doi: 10.1007/s10815-018-1346-7. Epub 2018 Oct 25.

PMID:
30362058
33.

Prenatal Diagnosis of Merosin-Deficient Muscular Dystrophy.

Fadiloglu E, Ozten G, Unal C, Talim B, Topaloglu H, Beksac MS.

Fetal Pediatr Pathol. 2018 Dec;37(6):418-423. doi: 10.1080/15513815.2018.1520944. Epub 2018 Oct 25.

PMID:
30358464
34.

Management and evaluation of pregnant women with Takayasu arteritis.

Tanacan A, Unal C, Yucesoy HM, Duru SA, Beksac MS.

Arch Gynecol Obstet. 2019 Jan;299(1):79-88. doi: 10.1007/s00404-018-4927-x. Epub 2018 Oct 9.

PMID:
30302544
35.

Methylenetetrahydrofolate Reductase Polymorphisms and Pregnancy Outcome.

Turgal M, Gumruk F, Karaagaoglu E, Beksac MS.

Geburtshilfe Frauenheilkd. 2018 Sep;78(9):871-878. doi: 10.1055/a-0664-8237. Epub 2018 Sep 14.

36.

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.

Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV.

Haematologica. 2018 Dec;103(12):2079-2087. doi: 10.3324/haematol.2018.194118. Epub 2018 Sep 20.

37.

Differential expression of leukemia inhibitory factor and insulin like growth factor-1 between normal pregnancies, partial hydatidiform moles and complete hydatidiform moles.

Yucel Cicek OS, Hekimoglu ER, Turgal M, Atilla P, Cakar AN, Usubutun A, Beksac MS.

Placenta. 2018 Sep;69:64-70. doi: 10.1016/j.placenta.2018.07.002. Epub 2018 Jul 6.

PMID:
30213486
38.

Gestational Outcomes of Pregnant Women Who Have Had Invasive Prenatal Testing for the Prenatal Diagnosis of Duchenne Muscular Dystrophy.

Beksac MS, Tanacan A, Aydin Hakli D, Orgul G, Soyak B, Balci Hayta B, Dincer P, Topaloğlu H.

J Pregnancy. 2018 Jul 30;2018:9718316. doi: 10.1155/2018/9718316. eCollection 2018.

39.

The safety of bortezomib for the treatment of multiple myeloma.

Cengiz Seval G, Beksac M.

Expert Opin Drug Saf. 2018 Sep;17(9):953-962. doi: 10.1080/14740338.2018.1513487. Epub 2018 Aug 30. Review.

PMID:
30118610
40.

Congenital central nervous system anomalies: the 10-year single center experience on a challenging issue in perinatal medicine.

Aydın E, Tanacan A, Büyükeren M, Uçkan H, Yurdakök M, Beksaç MS.

J Turk Ger Gynecol Assoc. 2018 Aug 6. doi: 10.4274/jtgga.2018.0079. [Epub ahead of print]

41.

Fatal Postpartum Hemorrhage in a Patient with Niemann-Pick Disease Type B.

Tanacan A, Yalcin A, Unal C, Akinci SB, Beksac MS.

Case Rep Obstet Gynecol. 2018 Jun 28;2018:9719374. doi: 10.1155/2018/9719374. eCollection 2018.

42.

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.

Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W, Dimopoulos M, Stankovic S, Durán MS, De Stefano V, Corso A, Kochkareva Y, Laane E, Berthou C, Salwender H, Masliak Z, Pečeliūnas V, Willenbacher W, Silva J, Louw V, Nemet D, Borbényi Z, Abadi U, Pedersen RS, Černelč P, Potamianou A, Couturier C, Feys C, Thoret-Bauchet F, Boccadoro M; EMMOS Investigators.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):e401-e419. doi: 10.1016/j.clml.2018.06.018. Epub 2018 Jun 25.

43.

Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?

Atilla E, Yalciner M, Atilla PA, Ates C, Bozdag SC, Yuksel MK, Toprak SK, Gunduz M, Ozen M, Akan H, Demirer T, Arslan O, Ilhan O, Beksac M, Ozcan M, Gurman G, Topcuoglu P.

Antivir Ther. 2018;23(8):647-653. doi: 10.3851/IMP3252.

PMID:
29972137
44.

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.

Jurczyszyn A, Castillo JJ, Avivi I, Czepiel J, Davila J, Vij R, Fiala MA, Gozzetti A, Grząśko N, Milunovic V, Hus I, Mądry K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Dębski J, Atilla E, Beksac M, Mele G, Sawicki W, Jayabalan D, Charliński G, Gyula Szabo A, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Crusoe E, Hungria V, Richardson P, Laubach J, Guerrero-Garcia T, Liu J, Vesole DH.

Leuk Lymphoma. 2019 Jan;60(1):118-123. doi: 10.1080/10428194.2018.1473574. Epub 2018 Jul 2.

PMID:
29965787
45.

Congenital heart defects: the 10-year experience at a single center.

Aydin E, Aypar E, Oktem A, Ozyuncu O, Yurdakok M, Guvener M, Demircin M, Beksac MS.

J Matern Fetal Neonatal Med. 2018 Jul 22:1-5. doi: 10.1080/14767058.2018.1491029. [Epub ahead of print]

PMID:
29914284
46.

Treatment of Rectovaginal Fistula Using Sphincteroplasty and Fistulectomy.

Beksac K, Tanacan A, Ozgul N, Beksac MS.

Obstet Gynecol Int. 2018 May 6;2018:5298214. doi: 10.1155/2018/5298214. eCollection 2018.

47.

Management of a Pregnancy with a Solid Pseudopapillary Neoplasm of the Pancreas.

Tanacan A, Orgul G, Dogrul AB, Aktoz F, Abbasoglu O, Beksac MS.

Case Rep Obstet Gynecol. 2018 Apr 16;2018:5832341. doi: 10.1155/2018/5832341. eCollection 2018.

48.

Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma.

Kumar S, Durie B, Nahi H, Vij R, Dimopoulos MA, Kastritis E, Terpos E, Leleu X, Beksac M, Goldschmidt H, Hillengass J, Su Z, Hutton B, Cameron C, Khan I, Lam A.

Leuk Lymphoma. 2019 Jan;60(1):163-171. doi: 10.1080/10428194.2018.1459609. Epub 2018 May 9.

PMID:
29741423
49.

Are Congenital Urinary Tract Abnormalities Linked to Maternal Methylenetetrahydrofolate Reductase Polymorphisms in Fetuses of Intentionally Terminated Pregnancies with Oligo- or Anhydramnios ?

Beksac MS, Beksac AT, Buyukeren M, Tanacan A, Bektas H, Gucer S.

Fetal Pediatr Pathol. 2018 Jun;37(3):177-183. doi: 10.1080/15513815.2018.1461283. Epub 2018 May 8.

PMID:
29737941
50.

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P.

Leukemia. 2018 Jul;32(7):1542-1560. doi: 10.1038/s41375-018-0040-1. Epub 2018 May 2. Review.

Supplemental Content

Loading ...
Support Center